LMG Life Sciences Honors Dechert Cross-Border Deal Team

Dechert’s life sciences capabilities were recognized when a Dechert deal – the acquisition by Italy’s Chiesi Farmaceutici of Nasdaq-listed Amryt Pharma – was named an “Impact Deal of the Year” in the LMG Life Sciences EMEA Awards 2024.

A multi-practice, multi-jurisdictional Dechert team advised Chiesi, a research-focused biopharmaceuticals group headquartered in Parma, Italy, in the US$1.48 billion acquisition of Amryt, a global commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare and orphan diseases.

The acquisition allows Chiesi, which develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care, to take ownership of Amryt’s significant rare disease medicine portfolio.

The deal also demonstrates Dechert’s ability to close complex cross-border mandates in the heavily regulated life sciences sector involving significant IP, corporate, and antitrust aspects.

The Dechert team, which involved lawyers from the firm’s offices in the U.S., UK, France, Belgium, and Germany, was led by corporate partners Alain Decombe, Michael Darby and David Rosenthal. An antitrust/competition team led by Mélanie Thill-Tayara, Clemens York, James Fishkin, Sophie Pele and Marion Provost also advised on the matter, in addition to teams from the firm’s intellectual property, labor, global tax and employee benefits practices.

Dechert and its lawyers were also highlighted in other categories of LMG Life Sciences’ EMEA awards. Mélanie Thill-Tayara, Paris-based antitrust partner and co-lead of the firm’ Life Sciences practice, was named a finalist for “Antitrust/Competition Lawyer of the Year,” while Paris-based national partner Marion Provost was shortlisted for “Regulatory Rising Star.”

Dechert itself was named a finalist in the jurisdictional categories as “France Firm of the Year.”

About Dechert 

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 20 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.